Aalto-Setälä K, Gylling H, Helve E, Kovanen P, Miettinen T A, Turtola H, Kontula K
Recombinant DNA Laboratory, University of Helsinki, Finland.
Hum Genet. 1989 Jul;82(4):305-7. doi: 10.1007/BF00273986.
An XbaI restriction fragment length polymorphism (RFLP) within the coding region of the apolipoprotein B (apoB) gene has been found to be associated with serum cholesterol and triglyceride levels in several populations. Mutations in another genetic locus, the low density lipoprotein (LDL) receptor gene, give rise to familial hypercholesterolemia (FH), a disease characterized by hypercholesterolemia, tendon xanthomas and atherosclerosis. We determined the XbaI genotypes and serum lipoprotein levels of 120 unrelated patients with the heterozygous form of FH. A non-parametric analysis of variance showed a significant association between elevated serum total cholesterol concentration (P less than 0.05), serum LDL-cholesterol concentration (P less than 0.025) and the presence of the XbaI restriction site (X2 allele). Thus, patients homozygous for the presence of the XbaI restriction site (genotype X2X2, n = 28) had on average a 14% higher serum total cholesterol level and a 21% higher serum LDL-cholesterol level than those homozygous for the absence of this site (genotype X1X1, n = 29); patients heterozygous for the XbaI restriction site (genotype X1X2, n = 63) had intermediate serum total and LDL-cholesterol levels. No significant differences were seen in serum triglyceride or high-density lipoprotein (HDL)-cholesterol values between these patient groups. These data demonstrate that genetic polymorphism of the principal ligand for the LDL receptor, apoB, may contribute to serum cholesterol regulation, even in patients with grossly distorted cholesterol homeostasis.
载脂蛋白B(apoB)基因编码区域内的XbaI限制性片段长度多态性(RFLP)已被发现与多个人群的血清胆固醇和甘油三酯水平相关。另一个基因位点,即低密度脂蛋白(LDL)受体基因的突变,会导致家族性高胆固醇血症(FH),这是一种以高胆固醇血症、肌腱黄色瘤和动脉粥样硬化为特征的疾病。我们测定了120名非亲属的杂合型FH患者的XbaI基因型和血清脂蛋白水平。非参数方差分析显示血清总胆固醇浓度升高(P小于0.05)、血清LDL胆固醇浓度升高(P小于0.025)与XbaI限制性位点(X2等位基因)的存在之间存在显著关联。因此,XbaI限制性位点纯合的患者(基因型X2X2,n = 28)的血清总胆固醇水平平均比该位点缺失纯合的患者(基因型X1X1,n = 29)高14%,血清LDL胆固醇水平高21%;XbaI限制性位点杂合的患者(基因型X1X2,n = 63)的血清总胆固醇和LDL胆固醇水平处于中间值。这些患者组之间的血清甘油三酯或高密度脂蛋白(HDL)胆固醇值没有显著差异。这些数据表明,即使在胆固醇稳态严重失调的患者中,LDL受体的主要配体apoB的基因多态性也可能有助于血清胆固醇的调节。